➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Boehringer Ingelheim
Colorcon
McKesson
Dow

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Patent: 10,011,659

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,011,659
Title:Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.
Inventor(s): Yarden; Yosef (Rehovot, IL), Mancini; Maicol (Rehovot, IL), Gaborit; Nadege (Rehovot, IL)
Assignee: Yeda Research and Development Co. Ltd. (Rehovot, IL)
Application Number:14/956,585
Patent Claims:see list of patent claims

Details for Patent 10,011,659

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28 ⤷  Free Forever Trial Yeda Research and Development Co. Ltd. (Rehovot, IL) 2034-09-08 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ⤷  Free Forever Trial Yeda Research and Development Co. Ltd. (Rehovot, IL) 2034-09-08 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ⤷  Free Forever Trial Yeda Research and Development Co. Ltd. (Rehovot, IL) 2034-09-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,011,659

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2016038610 ⤷  Free Forever Trial
United States of America 2016152712 ⤷  Free Forever Trial
Japan 2017534574 ⤷  Free Forever Trial
European Patent Office 3176183 ⤷  Free Forever Trial
European Patent Office 3191523 ⤷  Free Forever Trial
Canada 2959775 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Merck
Harvard Business School
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.